SpeeDx
SpeeDx is an Australian molecular diagnostics company that develops proprietary multiplex PCR IVD products — STI, respiratory, and enteric panels — and offers custom development and companion diagnostic services to reference labs, diagnostic OEMs, and pharma companies globally.
- Company typePrivate
- Founded2009
- HeadquartersSydney, Australia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What SpeeDx does
SpeeDx is an Australian molecular diagnostics company, founded in 2009 and headquartered in Sydney, that develops and commercializes multiplex PCR-based in vitro diagnostic (IVD) products for clinical laboratories. Its technology stack is built on a set of proprietary platforms — PlexZyme (core detection chemistry), PlexPCR (multiplex amplification), PlexPrime (mutation-specific amplification), PlexPlus (high-density simultaneous real-time detection enabling 12+ targets per well), and InSignia — which together underpin assays in three disease franchises: sexually transmitted infections (including antimicrobial resistance markers for gonorrhea and Mycoplasma genitalium), respiratory infections, and gastrointestinal infections, plus specialized research reagents and controls.
The company sells its products through an enterprise B2B motion: direct field sales to reference laboratories and diagnostic companies, complemented by a four-pillar services portfolio (Technology Partnering, Custom Development, Strategic Collaboration, and Co-Development Partnerships for companion diagnostics). Revenue is generated through one-time product licensing, professional services for custom assay development, and technology licensing royalties. Pricing is quote-based rather than list, consistent with enterprise reagent and CDx contracting. Named partners and customers include Cepheid, GSK, Biocartis, and Labcorp, and SpeeDx holds ISO-13485:2016 certification for medical device manufacturing.
SpeeDx operates from offices in Sydney, Austin, and London, and has raised approximately $59.8 million across disclosed rounds, most recently a $26 million round in February 2023 led by Northpond Ventures with Platinum Asset Management and Tenmile. The company is privately held (SpeeDx Pty Ltd) and was co-founded by CSO Dr Alison Todd. Its business model combines reagent kit sales, custom development services, technology licensing, and CDx co-development — a mix that monetizes its chemistry platform across multiple customer types but leaves revenue concentrated in a small set of enterprise accounts.
SpeeDx firmographics
Firmographics- Name
- SpeeDx
- Legal name
- SpeeDx Pty Ltd
- Website
- https://plexpcr.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- SpeeDx is an Australian molecular diagnostics company that develops proprietary multiplex PCR IVD products — STI, respiratory, and enteric panels — and offers custom development and companion diagnostic services to reference labs, diagnostic OEMs, and pharma companies globally.
- Ownership category
- akta.pro rank
SpeeDx industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industries
- Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels) (HLAHAOAJ), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
Keywords
Where SpeeDx is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
SpeeDx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Molecular Diagnostic Products: Sale of multiplexed IVD products including STI diagnostics, respiratory panels, and enteric testing solutions. Products detect infecting organisms along with antimicrobial resistance markers and provide prompt analysis of respiratory viruses.
- Custom Development Services: Bespoke product development services for laboratories and diagnostic companies, including assay design, regulatory strategy, and manufacturing scale-up support.
- Technology Licensing and Partnering: Licensing of proprietary multiplexing technologies to other industry players, including technology partnering, strategic collaboration, and co-development partnerships for companion diagnostics.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
SpeeDx product offering
Product offeringCore offering
SpeeDx develops, manufactures, and commercializes multiplex molecular diagnostic test kits built on proprietary PlexPCR®, PlexPrime®, PlexPlus®, PlexZyme®, and InSignia® technologies. Its product portfolio covers sexually transmitted infections (including gonorrhea and Mycoplasma genitalium with antimicrobial resistance markers), respiratory infections, and gastrointestinal infections, alongside research reagents and controls. The company also offers custom assay development, technology licensing, and co-development partnership services to diagnostic and pharmaceutical companies.
Product overview
SpeeDx offers a comprehensive molecular diagnostics platform built on proprietary multiplexing technologies. The core technology foundation is PlexZyme®, which enables high-sensitivity detection across all product lines. The technology portfolio includes PlexPCR® for high-specificity multiplex PCR, PlexPrime® for mutation differentiation, PlexPlus® for simultaneous real-time detection of up to 12+ targets per well, and InSignia® as an additional technology platform. The company commercializes multiplexed IVD products organized into three disease-focused product lines: STI Diagnostics (detecting organisms and AMR markers for GC and MG), Respiratory Infection Panels, and Enteric/Gastrointestinal Infection Panels. Additionally, SpeeDx provides Specialized Research Reagents and Controls & Accessories. The portfolio is complemented by four service offerings: Technology Partnering (industry access to proprietary technologies), Custom Development (laboratory-specific solutions), Strategic Collaboration (enhancing commercial diagnostics), and Co-Development (companion diagnostics for biotech/pharma).
Differentiator
Problem solved
Functional benefit
Brands
- PlexPCR: Proprietary multiplexing PCR technology platform
- PlexPrime
- PlexPlus
- PlexZyme
- InSignia
Products and services
- Sexually Transmitted Infections (STI) Diagnostic Solutions Multiplexed IVD test kits that detect key STI pathogens (including gonorrhea and Mycoplasma genitalium) together with antimicrobial resistance markers, provided as multiple target panels on an open-platform workflow for reference and clinical laboratories.
- Respiratory Infection Panels Multiplexed diagnostic panels that identify respiratory pathogens with reliable target differentiation, scalable sample throughput, and cost-effective reagents for clinical laboratories.
- Enteric/Gastrointestinal Infection Panels Flexible multiplexed solutions that detect bacteria, viruses, and parasites causing gastrointestinal illness, including comprehensive pathogen detection and mini panels for modular workflow integration in clinical laboratories.
- Specialized Research Reagents Targeted research assays, including flexible solutions detecting bacteria, viruses, and parasites, panels for fungi causing dermatophytosis, and expanded target selections for STI, respiratory, or lesion research.
- Controls & Accessories Quality control materials and accessories that support SpeeDx diagnostic testing workflows in customer laboratories.
- Custom Development Services Bespoke assay development service for laboratories and diagnostic companies, providing tailored solutions for specific needs and platform requirements using SpeeDx's proven development process.
- Technology Partnering Services Partnering service providing diagnostic industry access to SpeeDx's proprietary multiplexing technologies to enhance partner capabilities, including technology licensing arrangements.
- Co-Development Partnership Services Partnership service for biotech and pharmaceutical companies that leverages SpeeDx's multiplexing technologies to co-develop companion diagnostics (CDx) and complementary diagnostic products.
- Strategic Collaboration Services Collaboration service that combines SpeeDx's scientific and development expertise with diagnostic companies to enhance their commercial diagnostic offerings.
Quantifiable outcome
- 12+ targets per well with 2 readouts per channel vs 3-5 targets per well for competitors
- +2 more outcomes
Companies that use SpeeDx
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
SpeeDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SpeeDx partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- GSKminorPharmaceutical partner shown as trusted customer logo on SpeeDx website, suggesting collaboration in diagnostics development
- LabcorpminorLaboratory services company shown as trusted customer logo on SpeeDx website, indicating use of SpeeDx diagnostic products
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
SpeeDx competitors and assessment
Company assessmentDirect peers
- Cepheid (Danaher): Cepheid's GeneXpert system is the dominant sample-to-answer molecular diagnostics platform for infectious disease (including STI and respiratory menus). SpeeDx already lists Cepheid as a partner/customer, and both compete in multiplex PCR infectious-disease testing sold to reference laboratories.
- Hologic: Hologic's Panther system and Aptima assays are a leading molecular diagnostics franchise for sexually transmitted infections (chlamydia, gonorrhea, Mycoplasma genitalium). SpeeDx's STI panels — including MG and gonorrhea with AMR markers — directly compete with Hologic's STI menu on reference-lab benches.
- bioMérieux (BioFire): BioFire's FilmArray multiplex syndromic panels (respiratory, GI) are the benchmark for single-sample, many-pathogen testing in hospital labs. SpeeDx's respiratory and enteric product lines compete directly with FilmArray in multiplex syndromic infectious-disease workflows.
- Qiagen (QIAstat-Dx): Qiagen's QIAstat-Dx platform delivers multiplex syndromic respiratory and GI panels, and Qiagen also offers sample-prep and PCR reagent technologies for molecular diagnostics. The product and channel overlap with SpeeDx's respiratory and enteric menus makes it a direct peer.
- Becton Dickinson (BD MAX): BD's BD MAX system runs open and BD-developed multiplex molecular assays for STI, respiratory, and enteric pathogens. SpeeDx competes with BD MAX menu expansion in the same reference-lab and hospital channels.
- Biocartis: Biocartis develops the Idylla molecular diagnostics platform, a rapid, sample-to-answer PCR system with oncology and infectious-disease menus. SpeeDx lists Biocartis as a customer/partner, and both companies operate in the rapid PCR infectious-disease category.
Broad incumbents
- Roche Diagnostics: Roche's cobas systems and Liat point-of-care platform offer broad molecular diagnostics menus including STI, respiratory, and viral load. As the largest IVD player globally, Roche is a broad incumbent shaping the competitive context for SpeeDx's syndromic infectious-disease assays.
- Abbott Molecular: Abbott's m2000 and Alinity m platforms deliver molecular diagnostics across infectious disease, including STI and viral panels. As a broad incumbent with deep hospital and reference-lab penetration, Abbott shapes menu-standard dynamics SpeeDx must compete against.
- QuidelOrtho: QuidelOrtho (formed via merger of Quidel and Ortho Clinical Diagnostics) offers the Savanna multiplex PCR platform for infectious disease in addition to rapid antigen and immunoassay products. The Savanna platform directly overlaps SpeeDx's multiplex PCR positioning in hospital and reference labs.
Emerging players
- GenMark Diagnostics (now Roche): GenMark's ePlex system offers multiplex syndromic panels (respiratory, GI, bloodstream infections) for hospital labs, and was acquired by Roche. Its syndromic-panel approach is conceptually adjacent to SpeeDx's respiratory and enteric product strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
SpeeDx social profiles
Digital presenceSpeeDx compliance and trust
Trust signalCompliance1 record
SpeeDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
SpeeDx leadership team
Management profileNumber of profiles
Profiles3 records
SpeeDx funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SpeeDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SpeeDx
What does SpeeDx do?
SpeeDx develops, manufactures, and commercializes multiplex molecular diagnostic test kits built on proprietary PlexPCR®, PlexPrime®, PlexPlus®, PlexZyme®, and InSignia® technologies. Its product portfolio covers sexually transmitted infections (including gonorrhea and Mycoplasma genitalium with antimicrobial resistance markers), respiratory infections, and gastrointestinal infections, alongside research reagents and controls. The company also offers custom assay development, technology licensing, and co-development partnership services to diagnostic and pharmaceutical companies.
Is SpeeDx a public or private company?
SpeeDx is a private company. It is classified as venture growth investor backed and is currently operating.
When was SpeeDx founded?
SpeeDx was founded in 2009. It employs 51 to 100 people.
Where is SpeeDx based?
SpeeDx is headquartered in Sydney, Australia, in the Oceania region.
How does SpeeDx make money?
Three revenue lines are on record. Molecular Diagnostic Products are the primary driver. The others are custom Development Services and technology Licensing and Partnering.
Who are SpeeDx's main competitors?
Direct peers on record are Cepheid (Danaher), Hologic, bioMérieux (BioFire), Qiagen (QIAstat-Dx), Becton Dickinson (BD MAX) and Biocartis. Broad incumbents are Roche Diagnostics, Abbott Molecular and QuidelOrtho. GenMark Diagnostics (now Roche) is listed as an emerging player.
Does SpeeDx have an API?
No public API is recorded for SpeeDx.
What industry is SpeeDx in?
SpeeDx's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAHAOAJ, Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels). Its NAICS code is 325413 and its SIC code is 2835.